overate on tirzepatide Before and after tirzepatide weight
Description
Ready to talk options
In the STEP-1 trial published in The New England Journal of Medicine in 2021, once-weekly subcutaneous semaglutide at 2.4 mg produced a mean placebo-adjusted body weight reduction of 12.4% at 68 weeks in adults with overweight or obesity (Wilding et al., NEJM, 2021)
Here are several ways it can help: Appetite suppression Semaglutide mimics the GLP-1 hormone, which is released after you eat and signals the brain that you are full
The taste disturbance significantly affects your quality of life or adherence to treatment, as alternative therapeutic options may be available
